10 Best Agritech for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The agritech sector presents compelling opportunities for value-focused analysis amid fluctuating commodity prices and innovation in crop solutions. These 10 agritech stock picks were selected using ValueSense's proprietary intrinsic value methodology, prioritizing companies where current market prices appear below calculated intrinsic values, strong quality ratings (above 4.5 where possible), positive free cash flow generation, and exposure to fertilizers, potash, and biotech crop enhancements. Metrics like ROIC, FCF margins, gross margins, and debt-to-equity ratios guide the screening to highlight undervalued names across market caps from micro-cap innovators to large-cap leaders. This watchlist emphasizes educational analysis of financial health, growth potential, and risks in the agritech space, ideal for diversified stock watchlists.
Featured Stock Analysis
Stock #1: Nutrien Ltd. (NTR)
| Metric | Value |
|---|---|
| Market Cap | $33.7B |
| Quality Rating | 6.4 |
| Intrinsic Value | $51.5 |
| 1Y Return | 31.7% |
| Revenue | $26.3B |
| Free Cash Flow | $2,186.2M |
| Revenue Growth | (1.3%) |
| FCF margin | 8.3% |
| Gross margin | 30.4% |
| ROIC | 6.5% |
| Total Debt to Equity | 56.4% |
Investment Thesis
Nutrien Ltd. (NTR) stands out as a large-cap leader in the agritech space with a market cap of $33.7B and a solid quality rating of 6.4. Its intrinsic value is estimated at $51.5, suggesting potential undervaluation relative to current levels. The company generates robust revenue of $26.3B and free cash flow of $2,186.2M, supported by a healthy FCF margin of 8.3% and gross margin of 30.4%. Despite a slight revenue growth dip of 1.3%, its ROIC of 6.5% and 1Y return of 31.7% indicate resilient operations in fertilizers and crop nutrients. Total debt to equity at 56.4% remains manageable, positioning NTR for steady cash generation in commodities-driven agritech.
This analysis highlights NTR's scale advantages in a sector recovering from cyclical pressures, making it a cornerstone for value-oriented portfolios seeking stability.
Key Catalysts
- Strong $2.2B FCF supports dividends and buybacks amid fertilizer demand.
- 31.7% 1Y return reflects market recognition of operational efficiency.
- 6.5% ROIC signals efficient capital use in potash and nutrient production.
- 30.4% gross margin provides buffer against input cost volatility.
Risk Factors
- 1.3% revenue growth vulnerable to commodity price swings.
- 56.4% debt-to-equity could pressure finances if rates rise.
- Sector cyclicality tied to global agriculture demand.
Stock #2: CF Industries Holdings, Inc. (CF)
| Metric | Value |
|---|---|
| Market Cap | $15.0B |
| Quality Rating | 7.3 |
| Intrinsic Value | $131.7 |
| 1Y Return | 1.7% |
| Revenue | $6,736.0M |
| Free Cash Flow | $1,712.0M |
| Revenue Growth | 12.6% |
| FCF margin | 25.4% |
| Gross margin | 39.8% |
| ROIC | 13.1% |
| Total Debt to Equity | 44.1% |
Investment Thesis
CF Industries Holdings, Inc. (CF) earns a top quality rating of 7.3 with a $15.0B market cap, positioning it as a premium agritech pick. Intrinsic value at $131.7 points to significant upside potential. Key metrics include $6,736.0M revenue, impressive $1,712.0M free cash flow, and a standout 25.4% FCF margin. Positive 12.6% revenue growth, 39.8% gross margin, and 13.1% ROIC underscore operational strength, even with a modest 1.7% 1Y return. Debt-to-equity of 44.1% supports financial flexibility in nitrogen fertilizers.
CF's high margins and growth make it a standout for investors analyzing undervalued agritech stocks with cash flow durability.
Key Catalysts
- 25.4% FCF margin and $1.7B FCF enable reinvestment in expansions.
- 12.6% revenue growth driven by rising fertilizer needs.
- 13.1% ROIC highlights superior capital efficiency.
- 39.8% gross margin resilient to cost pressures.
Risk Factors
- Low 1.7% 1Y return amid market volatility.
- 44.1% debt-to-equity sensitive to interest rate changes.
- Dependence on nitrogen commodity cycles.
Stock #3: NOV Inc. (NOV)
| Metric | Value |
|---|---|
| Market Cap | $6,821.0M |
| Quality Rating | 5.8 |
| Intrinsic Value | $24.8 |
| 1Y Return | 26.8% |
| Revenue | $8,775.0M |
| Free Cash Flow | $877.0M |
| Revenue Growth | (1.4%) |
| FCF margin | 10.0% |
| Gross margin | 20.5% |
| ROIC | 7.4% |
| Total Debt to Equity | 36.2% |
Investment Thesis
NOV Inc. (NOV), with a $6,821.0M market cap and quality rating of 5.8, offers exposure to agritech-adjacent equipment solutions. Intrinsic value of $24.8 suggests value opportunity. It reports $8,775.0M revenue, $877.0M free cash flow, 10.0% FCF margin, and 20.5% gross margin. ROIC stands at 7.4%, with a solid 26.8% 1Y return, though revenue growth is 1.4%. Total debt to equity of 36.2% indicates balanced leverage.
NOV's metrics support analysis of mid-cap resilience in specialized agritech tools.
Key Catalysts
- 26.8% 1Y return shows momentum in equipment demand.
- 7.4% ROIC for efficient asset utilization.
- $877M FCF funds innovation.
- Moderate 36.2% debt aids stability.
Risk Factors
- 1.4% revenue growth risks from energy-agri ties.
- Cyclical exposure in NOV's operations.
- Margin pressure if input costs rise.
Stock #4: FMC Corporation (FMC)
| Metric | Value |
|---|---|
| Market Cap | $1,953.4M |
| Quality Rating | 4.5 |
| Intrinsic Value | $88.1 |
| 1Y Return | -72.0% |
| Revenue | $3,555.2M |
| Free Cash Flow | ($240.7M) |
| Revenue Growth | (14.7%) |
| FCF margin | (6.8%) |
| Gross margin | 37.2% |
| ROIC | (7.7%) |
| Total Debt to Equity | 33.5% |
Investment Thesis
FMC Corporation (FMC) has a $1,953.4M market cap and quality rating of 4.5, with intrinsic value at $88.1. Despite challenges like -72.0% 1Y return, $3,555.2M revenue, 37.2% gross margin, and 33.5% debt-to-equity provide a foundation. Free cash flow is negative at $240.7M with 6.8% FCF margin and 14.7% revenue growth, alongside 7.7% ROIC, this analysis frames FMC as a turnaround candidate in crop protection.
Educational review reveals potential in margins despite near-term headwinds.
Key Catalysts
- 37.2% gross margin supports recovery potential.
- Low 33.5% debt-to-equity for restructuring flexibility.
- Scale in $3.5B revenue base.
Risk Factors
- -72.0% 1Y return signals market concerns.
- Negative $240.7M FCF and 7.7% ROIC.
- 14.7% revenue decline ongoing.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #5: Intrepid Potash, Inc. (IPI)
| Metric | Value |
|---|---|
| Market Cap | $424.4M |
| Quality Rating | 6.1 |
| Intrinsic Value | $36.4 |
| 1Y Return | 21.1% |
| Revenue | $278.3M |
| Free Cash Flow | $46.2M |
| Revenue Growth | 8.9% |
| FCF margin | 16.6% |
| Gross margin | 16.8% |
| ROIC | (43.6%) |
| Total Debt to Equity | 1.5% |
Investment Thesis
Intrepid Potash, Inc. (IPI) features a $424.4M market cap, 6.1 quality rating, and $36.4 intrinsic value. Positive 21.1% 1Y return, $278.3M revenue, $46.2M FCF, 16.6% FCF margin, and 8.9% revenue growth shine, with 16.8% gross margin. However, 43.6% ROIC and minimal 1.5% debt-to-equity highlight a unique low-leverage profile in potash production.
This positions IPI for analysis in niche agritech value plays.
Key Catalysts
- 8.9% revenue growth and 21.1% 1Y return.
- 16.6% FCF margin with positive cash flow.
- Ultra-low 1.5% debt reduces risk.
Risk Factors
- 43.6% ROIC indicates capital inefficiency.
- Small-cap volatility in potash markets.
- Limited scale at $278M revenue.
Stock #6: American Vanguard Corporation (AVD)
| Metric | Value |
|---|---|
| Market Cap | $139.6M |
| Quality Rating | 4.7 |
| Intrinsic Value | $19.8 |
| 1Y Return | -16.6% |
| Revenue | $530.1M |
| Free Cash Flow | $2,989.0K |
| Revenue Growth | (4.3%) |
| FCF margin | 0.6% |
| Gross margin | 24.1% |
| ROIC | (17.1%) |
| Total Debt to Equity | 90.8% |
Investment Thesis
American Vanguard Corporation (AVD), $139.6M market cap, 4.7 quality rating, $19.8 intrinsic value. $530.1M revenue, minimal $2,989.0K FCF, 0.6% FCF margin, 24.1% gross margin, but -16.6% 1Y return, 4.3% revenue growth, 17.1% ROIC, and high 90.8% debt-to-equity. Analysis focuses on margin potential amid challenges.
Key Catalysts
- 24.1% gross margin for profitability path.
- Established $530M revenue in crop protection.
- Small-cap upside if execution improves.
Risk Factors
- -16.6% 1Y return and negative ROIC.
- High 90.8% debt burdens balance sheet.
- Weak 0.6% FCF margin.
Stock #7: Codexis, Inc. (CDXS)
| Metric | Value |
|---|---|
| Market Cap | $113.3M |
| Quality Rating | 6.2 |
| Intrinsic Value | $5.8 |
| 1Y Return | -72.4% |
| Revenue | $52.9M |
| Free Cash Flow | ($61.7M) |
| Revenue Growth | (17.9%) |
| FCF margin | (116.5%) |
| Gross margin | 79.3% |
| ROIC | (106.7%) |
| Total Debt to Equity | (90.7%) |
Investment Thesis
Codexis, Inc. (CDXS), $113.3M market cap, 6.2 quality rating, $5.8 intrinsic value. High 79.3% gross margin contrasts $52.9M revenue, $61.7M FCF, 116.5% FCF margin, -72.4% 1Y return, 17.9% revenue growth, 106.7% ROIC, and 90.7% debt-to-equity. Biotech enzyme focus offers speculative value analysis.
Key Catalysts
- Exceptional 79.3% gross margin in enzymes.
- Quality rating supports tech innovation.
- Micro-cap growth potential.
Risk Factors
- Severe -72.4% 1Y return and negative metrics.
- 106.7% ROIC signals losses.
- Cash burn from negative FCF.
Stock #8: Cibus, Inc. (CBUS)
| Metric | Value |
|---|---|
| Market Cap | $104.5M |
| Quality Rating | 4.6 |
| Intrinsic Value | $3.9 |
| 1Y Return | -23.5% |
| Revenue | $3,794.0K |
| Free Cash Flow | ($51.7M) |
| Revenue Growth | (8.6%) |
| FCF margin | (1,363.0%) |
| Gross margin | 83.8% |
| ROIC | (31.1%) |
| Total Debt to Equity | 65.3% |
Investment Thesis
Cibus, Inc. (CBUS), $104.5M market cap, 4.6 quality rating, $3.9 intrinsic value. Tiny $3,794.0K revenue, $51.7M FCF, 1,363.0% FCF margin, 83.8% gross margin, -23.5% 1Y return, 8.6% revenue growth, 31.1% ROIC, 65.3% debt-to-equity. Gene-editing analysis for high-risk innovators.
Key Catalysts
- 83.8% gross margin on limited revenue.
- Biotech pipeline potential.
- Intrinsic value upside.
Risk Factors
- Extreme 1,363% FCF margin negative.
- -23.5% 1Y return volatility.
- Negative ROIC and growth.
Stock #9: Bioceres Crop Solutions Corp. (BIOX)
| Metric | Value |
|---|---|
| Market Cap | $56.1M |
| Quality Rating | 4.7 |
| Intrinsic Value | $4.3 |
| 1Y Return | -88.0% |
| Revenue | $318.2M |
| Free Cash Flow | $12.0M |
| Revenue Growth | (27.9%) |
| FCF margin | 3.8% |
| Gross margin | 39.1% |
| ROIC | (1.4%) |
| Total Debt to Equity | 95.9% |
Investment Thesis
Bioceres Crop Solutions Corp. (BIOX), $56.1M market cap, 4.7 quality rating, $4.3 intrinsic value. $318.2M revenue, $12.0M FCF, 3.8% FCF margin, 39.1% gross margin, but -88.0% 1Y return, 27.9% revenue growth, 1.4% ROIC, 95.9% debt-to-equity. Crop solutions warrant cautious analysis.
Key Catalysts
- Positive $12M FCF amid challenges.
- 39.1% gross margin strength.
- Revenue scale potential.
Risk Factors
- -88.0% 1Y return sharp decline.
- High 95.9% debt.
- Negative growth and ROIC.
Stock #10: ImmuCell Corporation (ICCC)
| Metric | Value |
|---|---|
| Market Cap | $56.1M |
| Quality Rating | 6.8 |
| Intrinsic Value | $1,683.5 |
| 1Y Return | 10.7% |
| Revenue | $8,086.9M |
| Free Cash Flow | $2,691.1K |
| Revenue Growth | 34.1% |
| FCF margin | 0.0% |
| Gross margin | 41.6% |
| ROIC | 0.0% |
| Total Debt to Equity | 16.9% |
Investment Thesis
ImmuCell Corporation (ICCC), $56.1M market cap, strong 6.8 quality rating, outlier $1,683.5 intrinsic value. Massive $8,086.9M revenue, $2,691.1K FCF, 0.0% FCF margin, 41.6% gross margin, 34.1% revenue growth, 10.7% 1Y return, 0.0% ROIC, 16.9% debt-to-equity. Dairy/agritech analysis notes scale and growth.
Key Catalysts
- 34.1% revenue growth standout.
- High $8B revenue and quality score.
- Low 16.9% debt.
Risk Factors
- 0.0% ROIC/FCF margin efficiency gaps.
- Micro-cap risks despite metrics.
- Potential data anomalies in scale.
Portfolio Diversification Insights
These 10 agritech stocks cluster into large-cap stability (NTR, CF), mid-caps (NOV, FMC), and micro-cap innovators (IPI, AVD, CDXS, CBUS, BIOX, ICCC), with heavy fertilizer/potash tilt complemented by biotech and crop solutions. Allocate 40% to top quality (CF, ICCC, NTR) for cash flow, 30% mid for growth (NOV, IPI), 30% speculative for upside (CDXS, CBUS). Low correlations between commodities (NTR) and biotech (CDXS) enhance diversification, balancing ROIC leaders like CF 13.1% against turnaround plays like FMC.
Market Timing & Entry Strategies
Consider entry on dips below intrinsic values (e.g., NTR under $51.5), post-earnings for growth confirms like CF's 12.6% revenue, or sector rotations into agritech amid food security trends. Scale in over 3-6 months using dollar-cost averaging, monitoring FCF trends and debt levels. Watch commodity cycles for NTR/IPI, biotech catalysts for CDXS/CBUS.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
Selected via ValueSense intrinsic value tools, focusing on quality ratings above 4.5, FCF generation, and undervaluation in agritech sectors like fertilizers and biotech.
What's the best stock from this list?
CF Industries (CF) leads with 7.3 quality rating, 25.4% FCF margin, and 13.1% ROIC, offering balanced strength.
Should I buy all these stocks or diversify?
Diversify across large/mid/micro caps for risk balance; not all simultaneously due to sector correlations.
What are the biggest risks with these picks?
Commodity volatility, negative FCF/ROIC in some (FMC, CDXS), high debt (AVD, BIOX), and micro-cap illiquidity.
When is the best time to invest in these stocks?
On price pullbacks to intrinsic values, positive revenue inflection, or agritech demand surges from global trends.